News

Euclid Vision Welcomes Specialty Eyecare Professional to Commercial Team

Euclid Vision Corp., a global leader in specialty contact lenses and proactive myopia management initiatives, is pleased to announce the continued expansion of its U.S. sales team with the addition of Jon R. Hudson, ABOC, NCLEC, who has joined the company as account executive for Texas, and Central and Southern U.S. territories. Jon brings 24 years of experience in the eye care industry to his new role.

“We are all very excited to have Jon join our commercial team. The addition of Jon to the U.S. sales force will enable Euclid and Visionary Optics to assist more eye care professionals (ECPs) in providing best-in-class services to more patients, and reinforces our commitment to ECPs and their patients,” said David Bland, Euclid Vision, vice president of sales.

Jon started his career in the eye care industry as a lab technician and optician in both retail and independent eye care practices and followed that by managing independent eye care practices prior to branching off on his own as a practice management consultant. His time with independent practices was focused primarily on maximizing per patient revenue, including the implementation of myopia management programs and initiatives designed to add scleral lenses as a treatment option. Myopia is the leading cause of visual impairment in children worldwide, and its incidence and prevalence are on the rise, with estimates suggesting that more than half of the world’s population will be myopic by 2050. Jon’s passion for myopia management led to his employment with CooperVision Specialty EyeCare, where he held various roles over the course of six years. His primary focus involved development of practice management initiatives for myopia management and training the sales team on implementation of those programs.

Euclid Vision acquired Visionary Optics, a specialty scleral contact lens design and manufacturing pioneer, in 2022. The union of these two companies increases each establishment’s ability to provide comprehensive specialty contact lens care to more patients globally.  “As Euclid Vision and Visionary Optics focus on assisting more ECPs with their efforts to deliver best-in-class specialty contact lens services, in areas such as orthokeratology, scleral, and keratoconus management, Jon’s expansive experience in all sectors of eye care is the perfect fit for our commercial team and the customers we serve in this geographic region,” said Bland.

 

Learn more here.

Recent News

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin

07/07/2026

United Therapeutics Corporation Acquires Thymmune Therapeutics

United Therapeutics Corporation (Nasdaq: UTHR) announced it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The thymus is a critical organ for the development and proper function of key parts of the